With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...

AAVB-039 advances gene therapy for Stargardt disease, aiming for innovative treatments for inherited retinal disorders.

Nanoscope Therapeutics begins rolling submission of BLA to US FDA for gene-agnostic therapy, MCO-010 to treat retinitis pigmentosa: Dallas, Texas Wednesday, July 16, 2025, 14:30 H ...

MILAN, Italy I July 15, 2025 I AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company developing next-generation gene therapies for inherited ...

US biotech Nanoscope Therapeutics has begun a rolling submission to the American medicines regulator for MCO-010, the first ...

DALLAS, TX, USA I July 14, 2025 I Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel gene-agnostic ...

Nanoscope’s BLA has been granted rolling review by the FDA, with the first modules already submitted. The completion of the ...

Female sex hormones can significantly enhance the progression of the rare neurodegenerative eye disease retinitis pigmentosa (RP), according to a preclinical study by researchers at UT Southwestern ...

Beacon Therapeutics has completed the enrolment in its randomised, registrational Phase II/III VISTA trial of laru-zova (laruparetigene zovaparvovec) as a potential treatment for X-linked retinitis ...

The Phase I/IIa CLARICO trial of OpCT-001 marks the first clinical trial of an investigational induced pluripotent stem ...

Bayer’s BAYRY wholly owned subsidiary, BlueRock Therapeutics, announced that the first patient in the phase I/IIa CLARICO study has received OpCT-001, an investigational iPSC-derived cell therapy, ...

The global retinitis pigmentosa market, valued at $11.31 billion in 2024, is expected to grow to $25.87 billion by 2034, driven by gene therapy advancements, aging populations, and strategic ...